Navigation Links
Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
Date:12/8/2008

Novavax's first vaccine candidate for the prevention of RSV

ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Dr. Trudy Morrison, PhD, Professor of Molecular Genetics and Microbiology, University of Massachusetts Medical School, will be presenting the results of a preclinical study of a vaccine candidate for the prevention of respiratory syncytial virus ("RSV") at the 2nd Vaccine Congress in Boston, MA on December 9, 2008. This study was funded by Novavax, Inc., which has exclusive rights to develop and commercialize Paramyxovirus vaccines incorporating certain Virus-Like-Particles (VLPs) under a licensing agreement with the University of Massachusetts Medical School.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Research and ... Acute Ischemic Stroke Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Stroke Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Ischemic Stroke epidemiology, Acute ...
(Date:5/3/2016)... , May 3, 2016 BioNovus Innovations ... Institute for Advancing Medical Innovation (IAMI) today announced ... drugs, diagnostics and medical devices. An ... with rights to license, develop and commercialize medical ... "This partnership represents a significant advance ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 2016 , ... A new collaboration will give more researchers access to the ... and analytics leader SAS will provide researchers worldwide with data management and analytics tools ... System. , The DCRI and SAS share the goal of greater transparency and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today ... central New Jersey residents. What started out as an idea to provide a ... integrated approach to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , ...
(Date:5/4/2016)... ... ... Dr. Elyson and Dr. Assili, dentist in Northridge , announce that ... a common dental procedure, is performed for many adolescents and young adults today. While ... of complications. By providing wisdom tooth removal surgery at their office, Dr. Elyson and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Recognizing that lifestyle medicine is essential to health ... have tapped David Katz, MD, MPH, president of the American College of Lifestyle Medicine, ... medicine is especially gratifying,” said Katz. “There is so much opportunity to add years ...
(Date:5/4/2016)... ... May 04, 2016 , ... Pharmacy ... announced that it was chosen as the Pharmaceutical News Provider of the Year ... awards acknowledge the hard work and dedication of community members who strive to ...
Breaking Medicine News(10 mins):